Study of the Safety and Efficacy of CC-5013 Treatment For Patients With Myelodysplastic Syndrome
Completed · Phase 2
Conditions studied: Myelodysplastic Syndrome
In brief
To estimate the percent of patients with myelodysplastic syndromes (MDS) who experience erythroid response and the interval to response with daily treatment of 25 mg of CC-5013 .
Key facts
- Study ID
- NCT00044382
- Run by
- Celgene
- People needed
- 25
- Starts
- 2002-02-01
- Expected to finish
- 2007-01-30
- Last updated by the study team
- 2019-11-08
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Arizona Cancer Center — Tucson, Arizona, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.